ZYME NASDAQ
Zymeworks Inc.
1W: +7.2%
1M: +6.4%
3M: +31.1%
YTD: +8.4%
1Y: +62.6%
3Y: +301.2%
5Y: +26.5%
$28.85
+0.48 (+1.69%)
After Hours: $28.44 (-0.41, -1.44%)
Weekly Expected Move ±6.7%
$24
$26
$28
$30
$32
Credit Risk of going bust: lower than 54% of companies Debt: 11.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.39 (down 99%), Zymeworks Inc. would be worth roughly what it owes.
Total debt $268.6M against a stock market value of $2.04B.
Distance to default 5.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.6M (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' -7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.39 (down 99%), Zymeworks Inc. would be worth roughly what it owes.
Total debt $268.6M against a stock market value of $2.04B.
Distance to default 5.50 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $129.6M (short-term plus half of long-term), stock volatility 52.7%; Altman Z'' -7.73. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
20 relationships19
As Filer
counterparties named
1
As Counterparty
mentioned by others
2
Rel. Types
2022-10-19
Earliest Filing
2026-03-02
Latest Filing
partner: 16
investor: 3
Counterparties (Filed by ZYME)
19 relationshipsCompanies named in ZYME's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jazz Pharmaceuticals Ireland Limited | JAZZ | partner | Counterparty to the Amended and Restated License and Collaboration Agreement regarding Ziihera royalties. | 2026-03-02 | View |
| BeOne Medicines Ltd | — | partner | Counterparty to the License and Collaboration Agreement and Three-Party Royalty Payment Agreement regarding Ziihera roya | 2026-03-02 | View |
| BeOne Pharmaceutical (Suzhou) Co., Ltd | — | partner | Counterparty to the Three-Party Royalty Payment Agreement regarding Ziihera royalties. | 2026-03-02 | View |
| EcoR1 Capital Fund, L.P. | — | investor | Purchaser of Pre-Funded Warrants and beneficial owner of more than 5% of common stock | 2025-06-27 | View |
| EcoR1 Capital Fund Qualified, L.P. | — | investor | Purchaser of Pre-Funded Warrants and beneficial owner of more than 5% of common stock | 2025-06-27 | View |
| EcoR1 Capital LLC | — | investor | Affiliate of the Purchasers and manager of EcoR1 Capital Fund, L.P. | 2025-06-27 | View |
| Jazz Pharmaceuticals plc | JAZZ | partner | Parent company of Jazz Pharmaceuticals Ireland Limited and Jazz Inc., entered into an amended collaboration agreement an | 2023-05-16 | View |
| Jazz Pharmaceuticals Ireland Limited | JAZZ | partner | Subsidiary of Jazz Pharmaceuticals plc, entered into an amended license and collaboration agreement with Zymeworks BC In | 2023-05-16 | View |
| Jazz Inc. | JAZZ | partner | Affiliate of Jazz Pharmaceuticals Inc., entered into a stock and asset purchase agreement with Zymeworks subsidiaries to | 2023-05-16 | View |
| BeiGene, Ltd. | BEAM | partner | Existing partner holding an agreement with Zymeworks BC Inc. for Asia Pacific territories, referenced in the scope of th | 2023-05-16 | View |
| Jazz Pharmaceuticals, Inc. | JAZZ | partner | Partner acquiring assets and taking over development and commercialization of zanidatamab | 2023-04-26 | View |
| Zymeworks BC Inc. | ZYME | partner | Subsidiary transferring assets and entering amended collaboration agreement | 2023-04-26 | View |
| Zymeworks Biopharmaceuticals Inc. | ZYME | partner | Subsidiary transferring stock of ZZI and assets to Jazz | 2023-04-26 | View |
| Zymeworks Zanidatamab Inc. | ZYME | partner | Subsidiary whose stock is acquired by Jazz | 2023-04-26 | View |
| Jazz Pharmaceuticals Ireland Limited | JAZZ | partner | Affiliate of Jazz entering amended collaboration agreement | 2023-04-26 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the at-the-market offering of common stock | 2022-11-09 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Company's common stock under an Open Market Sale Agreement. | 2022-10-21 | View |
| Jazz Pharmaceuticals Ireland Limited | JAZZ | partner | Entered into a License and Collaboration Agreement granting exclusive rights to develop and commercialize zanidatamab in | 2022-10-19 | View |
| BeiGene, Ltd. | — | partner | Holds exclusive rights to commercialize zanidatamab in countries excluded from the Jazz agreement. | 2022-10-19 | View |
Mentioned As Counterparty
1 mentionsOther companies that named ZYME in their SEC 8-K filings.
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-09-23 | Material Agreement; Acquisition/Disposition; Financial Obligation; Regulation FD; Exhibits | Agreement Acquisition | View |
| 2026-08-25 | Regulation FD; Other Events; Exhibits | View | |
| 2026-08-06 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-06-29 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-05-14 | Regulation FD; Other Events; Exhibits | View | |
| 2026-05-07 | Earnings Release; Regulation FD; Exhibits | View | |
| 2026-04-01 | Officer/Director Change; Exhibits | View | |
| 2026-03-02 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Regulation FD Dis | Agreement | View |
| 2026-03-02 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2026-01-12 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-12-30 | Submission of Matters to a Vote of Security Holders | View | |
| 2025-11-18 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Other Events; Fi | View | |
| 2025-11-17 | Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-09-02 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-11 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Departure/Electio | Agreement | View |
| 2025-08-07 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-06-27 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-05-30 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR